Investment analysts at StockNews.com started coverage on shares of BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) in a research note issued to investors on Saturday. The firm set a “hold” rating on the stock.
BiondVax Pharmaceuticals Stock Up 0.3 %
Shares of NASDAQ BVXV opened at $1.82 on Friday. The company has a 50 day simple moving average of $1.94 and a 200 day simple moving average of $3.74. The company has a debt-to-equity ratio of 5.92, a current ratio of 4.28 and a quick ratio of 4.28. BiondVax Pharmaceuticals has a 1 year low of $1.70 and a 1 year high of $13.80. The firm has a market cap of $3.40 million, a PE ratio of -0.51 and a beta of 2.47.
BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) last released its quarterly earnings results on Monday, April 17th. The company reported ($0.30) earnings per share (EPS) for the quarter.
Institutional Trading of BiondVax Pharmaceuticals
About BiondVax Pharmaceuticals
BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza.
- Get a free copy of the StockNews.com research report on BiondVax Pharmaceuticals (BVXV)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for BiondVax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.